Encyclopedia of Law and Economics

Living Edition
| Editors: Alain Marciano, Giovanni Battista Ramello

Drug Price Regulation

  • Jean-Michel Josselin
  • Laurie Rachet Jacquet
  • Véronique Raimond
  • Lise Rochaix
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-7883-6_714-1

Abstract

Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failures associated with drug specificities. Explicit economic reasoning through the so-called health technology assessment framework is increasingly embedded in the institutional and administrative process of the evaluation procedure leading to market access, pricing and reimbursement for new drugs.

Keywords

Health Technology Assessment Drug Price National Health Insurance Scheme Sickness Fund Pharmaceutical Firm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973Google Scholar
  2. Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki P, Nasser M, Xerri B (2009) Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 87:339–367CrossRefGoogle Scholar
  3. Drummond M, Sculpher M, Claxton K, Stoddart G , Torrance G (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, New YorkGoogle Scholar
  4. Franken M, Heintz E, Gerber-Grote A, Raftery J (2016) Health economics as rhetoric: the limited impact of health economics on funding decisions in four European countries. Value Health 19:951–956CrossRefGoogle Scholar
  5. Gerber-Grote A, Sandmann G, Zhou M, Thoren T, Schwalm A, Weigel C, Balg C, Mensch A, Mostardt S, Seidl A, Lhachimi K (2014) Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty? Z Evid Fortbild Qual Gesundhwes 108:390–396CrossRefGoogle Scholar
  6. Grossman M (1972) On the concept of health capital and the demand for health. J Polit Econ 80:223–255CrossRefGoogle Scholar
  7. Heintz E, Gerber-Grote A, Ghabri S, Hamers F, Prevolnik Rupel V, Slabe-Erker R, Davidson T (2016) Is there a European view on health economic evaluation? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics 34:59–76CrossRefGoogle Scholar
  8. Hurley J (2000) An overview of the normative economics of the health sector. In: Culyer A, Newhouse J (eds) Handbook of health economics. Elsevier, Amsterdam, pp 55–118Google Scholar
  9. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Sullivan S, Mauskopf J et al (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17:5–14CrossRefGoogle Scholar
  10. Klingler C, Shah M, Barron J, Wright S (2013) Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German efficiency frontier approach. Health Policy 109:270–280CrossRefGoogle Scholar
  11. Mauskopf J (1998) Prevalence-based economic evaluation. Value Health 1:251–259CrossRefGoogle Scholar
  12. Mauskopf J (2014) Budget-impact analysis. In: Culyer A (ed) Encyclopedia of health economics, vol 1. Elsevier, Amsterdam, pp 98–107CrossRefGoogle Scholar
  13. Mauskopf J, Earnshaw S (2016) A methodological review of US budget-impact models for new drugs. PharmacoEconomics 34:1111–1131CrossRefGoogle Scholar
  14. McCabe C, Claxton K, Culyer A (2008) The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 26:733–744CrossRefGoogle Scholar
  15. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64CrossRefGoogle Scholar
  16. Morris S, Devlin N, Parkin D (2007) Economic analysis in health care. Wiley, New YorkGoogle Scholar
  17. Rice T, Rosenau P, Unruh L, Barnes A, Saltman R, van Ginneken E (2013) United States of America: health system review. Health Syst Transit 15:70–80Google Scholar
  18. Sorenson C, Chalkidou K (2012) Reflections on the evolution of health technology assessment in Europe. Health Econ Policy Law 7:25–45CrossRefGoogle Scholar
  19. Walton S, Basu A, Mullahy J, Hong S, Schumock G (2017) Measuring the value of pharmaceuticals in the US health system. PharmacoEconomics 35:1–4CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Jean-Michel Josselin
    • 1
  • Laurie Rachet Jacquet
    • 2
  • Véronique Raimond
    • 3
  • Lise Rochaix
    • 2
  1. 1.University of Rennes 1 and CREM UMR-CNRSRennesFrance
  2. 2.HospinnomicsParis School of EconomicsParisFrance
  3. 3.Haute Autorité de santéSaint-DenisFrance